136 related articles for article (PubMed ID: 12397554)
1. [Detection of DPD exon 14 skipping before fluorouracil treatment].
Steiner M; Schuff-Warner P; Hartung G
Dtsch Med Wochenschr; 2002 Oct; 127(42):2223. PubMed ID: 12397554
[No Abstract] [Full Text] [Related]
2. [Detection of DPD-exon-14 skipping before 5-fluorouracil treatment?].
Kliche KO
Dtsch Med Wochenschr; 2002 Mar; 127(9):463-4. PubMed ID: 11870563
[No Abstract] [Full Text] [Related]
3. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
4. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Innocenti F; Ratain MJ
Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
[No Abstract] [Full Text] [Related]
5. Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation.
van Kuilenburg AB; Vreken P; Beex LV; De Abreu RA; van Gennip AH
J Inherit Metab Dis; 1998 Jun; 21(3):280-4. PubMed ID: 9686375
[No Abstract] [Full Text] [Related]
6. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; van Gennip AH
Eur J Cancer; 1997 Nov; 33(13):2258-64. PubMed ID: 9470816
[TBL] [Abstract][Full Text] [Related]
7. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Gardiner SJ; Begg EJ; Robinson BA
Adverse Drug React Toxicol Rev; 2002; 21(1-2):1-16. PubMed ID: 12140902
[TBL] [Abstract][Full Text] [Related]
8. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
van Kuilenburg AB; Baars JW; Meinsma R; van Gennip AH
Ann Oncol; 2003 Feb; 14(2):341-2. PubMed ID: 12562666
[No Abstract] [Full Text] [Related]
9. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Ezzeldin H; Diasio R
Clin Colorectal Cancer; 2004 Sep; 4(3):181-9. PubMed ID: 15377401
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
13. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
Maring JG; van Kuilenburg AB; Haasjes J; Piersma H; Groen HJ; Uges DR; Van Gennip AH; De Vries EG
Br J Cancer; 2002 Apr; 86(7):1028-33. PubMed ID: 11953843
[TBL] [Abstract][Full Text] [Related]
14. Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients.
Celik I; Kars A; Guc D; Tekuzman G; Ruacan S
Cancer Invest; 2002; 20(3):333-9. PubMed ID: 12025228
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
16. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.
Yamaguchi K; Arai Y; Kanda Y; Akagi K
Jpn J Cancer Res; 2001 Mar; 92(3):337-42. PubMed ID: 11267945
[TBL] [Abstract][Full Text] [Related]
17. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
Gross E; Seck K; Kiechle M
Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.
Kouwaki M; Hamajima N; Sumi S; Nonaka M; Sasaki M; Dobashi K; Kidouchi K; Togari H; Wada Y
Clin Cancer Res; 1998 Dec; 4(12):2999-3004. PubMed ID: 9865912
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
20. Common DPYD mutation associated with 5-fluorouracil toxicity detected by PCR-mediated site-directed mutagenesis.
Jézéquel P; Joalland MP; Milano G; Lanoë D; Ricolleau G; Marie-Christine E; Deporte-Fety R
Clin Chem; 2000 Feb; 46(2):309-10. PubMed ID: 10657402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
